CTOs on the Move

Pionyr Immunotherapeutics

www.precisionimmune.com

 
Pionyr Immuntherapeutics (formerly Precision Immune Inc.) is developing cancer immunotherapies that target the tumor microenvironment to enhance the body`s antitumor immunity. The company is exploiting novel target discovery and antibody generation platform technologies to create the next generation of immuno-oncology therapeutics. The company`s approach, Myeloid Tuning™, is designed to enhance the immune system`s anti-tumor response by altering the cellular infiltrate of the tumor microenvironment with high specificity.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Pionyr Immunotherapeutics raised $62M on 12/13/2017

Similar Companies

Luzsana Biotechnology

Luzsana Biotechnology™ is a new kind of biotech company with a mission to make innovative medicines available, accessible, and affordable to anyone, anywhere.

Ikena Oncology

Ikena Oncology is a clinical-stage biotechnology company that discovers and develops patient-directed, biomarker-driven therapies for cancer patients.

OncoArendi Therapeutics

OncoArendi Therapeutics SA (WSE:OAT) is a Polish innovative biotechnology company specializing in research, development and commercialization of innovative small molecule drugs for treatment of respiratory diseases and cancer.

Pearson Dental Supply

Pearson Dental Supply is a Sylmar, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cerulean

The Cerulean team is committed to improving treatment for people living with cancer. We apply our Dynamic Tumor Targeting Platform to create a portfolio of NDCs designed to selectively attack tumor cells, reduce toxicity by sparing the body’s normal cells, and enable therapeutic combinations. Our first platform-generated candidate, CRLX101, is in multiple clinical trials in combination with other cancer treatments, all of which aim to unlock the power of combination therapy. Our second platform-generated candidate, CRLX301, is in a Phase 1/2a clinical trial.